BioCentury
ARTICLE | Financial News

Aldeyra stock surge continues

September 14, 2017 11:56 PM UTC

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) jumped $4.45 (70%) to $10.80 on Thursday as momentum continued following a Phase IIa data readout on Tuesday showing that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry eye disease (see BioCentury Extra, Sept. 12).

The company has more than doubled in value since releasing the data, adding nearly $100 million in market cap to finish with an equity valuation of $163.6 million as of Thursday's close...